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The metabolism of arachidonic acid by platelets in nephrotic syndrome.
The production of malondialdehyde (MDA) and thromboxane B2
(TxB2) by platelets following an arachidonic acid (AA) challenge was
greater in nephrotic platelet rich plasma (PRP) than in normal PRP. The
uptake of '4C-AA, and its subsequent conversion to '4C-TxB2 following
a thrombin stimulus, was also greater in nephrotic than normal PRP.
Normal plasma diminished the MDA production by nephrotic platelets.
The addition of albumin to nephrotic PRP, or, the intravenous infusion
of albumin in quantities sufficient to correct hypoalbuminemia also
diminished the excessive production of prostaglandin metabolites by
nephrotic platelets. The platelet aggregate ratio (PAR), which measures
circulating platelet aggregates, was abnormal during the acute phase of
nephrotic syndrome but reverted to normal following remission. These
data indicate that hypoalbuminemia is associated with increased AA
metabolism by platelets and suggest that platelet "hyperactivity" may
contribute to the proclivity toward thrombosis observed in nephrotic
syndrome.
Le métabolisme de l'acide arachidonique par les plaquettes an cours du
syndrome néphrotique. La production de malondialdthyde (MDA) et de
thromboxane B2 (TxB2) par les plaquettes après une stimulation par
l'acide arachidonique (AA) ëtait plus forte dans un plasma néphrotique
enrich en plaquettes (PRP) que dans un PRP normal. La captation de
'4C-AA, et sa conversion ultrieure en '4C-TxB2 apres un stimulus
thrombinique, étaient egalement plus fortes dans le PRP nëphrotique
que dans le PRP normal. Le plasma normal diminuait Ia production de
MDA par les plaquettes néphrotiques. L'addition d'albumine a du PRP
néphrotique, ou, Ia perfusion intraveineuse d'albumine en quantite
suffisante pour corriger l'hypo-albuminémie diminuaient également Ia
production excessive des métabolites des prostaglandines par les pla-
quettes néphrotiques. Le rapport d'aggrégation plaquettaire (PAR) qui
mesure les aggrégats plaquettaires circulants était anormal pendant Ia
phase aiguë du syndrome néphrotique mais retournait a Ia normale
après remission. Ces donnCes indiquent que l'hypoalbuminemie est
associee a une augmentation du métabolisme de l'AA par les plaquettes
et suggerent que "l'hyper-activite" plauqettaire pourrait contribuer a Ia
tendance a la thrombose observée au cours du syndrome nephrotique.
The "hypercoagulable" state of nephrotic syndrome has
been the subject of numerous studies. Increased levels of
factors V, VII, VIII, and X, and fibrinogen [1—6], decreased
levels of plasminogen and antithrombin III [7, 8], and platelet
"hyperactivity" [9—16] have all been described. Platelet rich
plasma obtained from patients with nephrotic syndrome demon-
strates spontaneous aggregation and enhanced aggregation to
arachidonic acid, ADP, collagen, and epinephnne [9—15]. In-
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creased plasma levels of the platelet specific protein, beta
thromboglobulin [13, 15, 16], and decreased in vivo platelet
survival [12] provide further evidence for platelet "hyperactivi-
ty" in this disorder.
In 1973, Bang et al [9] demonstrated that platelet "hyperag-
gregability" in nephrotic syndrome was inversely proportional
to the serum albumin concentration. Subsequently, several
laboratories showed that the addition of albumin in vitro [10, 11,
15] or in vivo [10, 11] corrected this defect. This suggests that
platelet hyperfunction in nephrotic syndrome may be related to
hypoalbuminemia. Since albumin binds arachidonic acid (AA)
and limits its conversion to thromboxane A2 by platelets in vitro
[17, 18], a normal albumin concentration may provide an
important modulating influence on platelet responsiveness in
vivo. Accordingly, we have studied the effects of albumin on
the AA metabolism of platelets obtained from patients with
nephrotic syndrome.
Methods
Patients. Nineteen patients with nephrotic syndrome were
studied. Renal function was evaluated by determinations of
serum creatinine, blood urea nitrogen, quantitative urinary
excretion of protein, 24-hr creatinine clearance, and percutane-
ous renal biopsy studied by light and immunofluorescent mi-
croscopy. The diagnosis of nephrotic syndrome was based on
criteria suggested by Schreiner [19]. Serum albumin concentra-
tions ranged between 1.1 to 3.0 g/dl.
Initial tests. Nine volumes of blood, drawn from the antecu-
bital vein following an overnight fast, were mixed with one
volume of 3.8 g% trisodium citrate. Platelet rich plasma (PRP)
was obtained by centrifugation at x200g for 15 mm at room
temperature; the platelet count was adjusted to 3 x l05/pi with
autologous platelet poor plasma. All tests were performed
within 2 hr of blood collection in a nitrogen atmosphere. All
patients did not ingest aspirin or other platelet inhibitors for at
least 2 weeks prior to the study.
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Malondialdehyde assay. Malondialdehyde formation was
measured according to the method of Smith, Ingerman, and
Silver [201, as modified by Villa, Livio, and de Gaetano [211.
Sodium arachidonate (90% pure: Sigma Chemical Company, St.
Louis, Missouri) was dissolved in 25 m sodium carbonate and
stored under nitrogen at —20°C until use. Sodium arachidonate
in final concentrations ranging between 0.25 and 1.0 mt was
added to PRP pre-incubated at 37°C for 1 mm. After a 5-mm
incubation, the reaction was stopped by the addition of 0.5 ml of
100% trichloroacetic acid (w/v) in 1.0 N HCI, The reaction
mixtures were centrifuged at x 1500g for 10 mm at 4°C. Each
supernatant was mixed with 0.5 ml of 0.12 M thiobarbituric acid
(Merck, Darmstaad, Germany) dissolved in 0.26 M Tris buffer
(pH 7.0), heated to 70° to 90°C for 30 mm, and then cooled to
room temperature. MDA was measured spectrophotometrically
by determining the absorbance peak at 532 nm using a spectro-
photometer (Spectracomp 601, Carlo Erba-Farmitalia, Milan,
Italy). Absorbance peaks of PRP and AA blanks were subtract-
ed from test values, and final results were derived from
simultaneously run standards containing known amounts of
malondialdehyde.
RIA for thromboxane B2 (TxB2). One-milliliter aliquots of
PRP were incubated at 37°C with 0.25 to 1.0 m sodium
arachidonate. After a 2-mm incubation, a 100-id aliquot was
removed and added to 400 d of a buffered solution containing 2
g/m1 indomethacin (Merck, Sharp & Dohme, Rahway, New
Jersey). The samples were then vortexed and frozen in liquid
nitrogen at —80°C. Subsequently, the samples were thawed and
spun at x 12,500g for 3 mm, and the supernatants were stored at
—20°C. At the time of assay, samples were diluted 1:5000-
1:15000 in 20 m phosphate buffer (pH 7.4) and assayed in a
volume of 1.5 ml. 3H-TxB2 (5000 dpm, New England Nuclear
Corp., Boston, Massachusetts, sp act 150 Cilmmole) and appro-
priately diluted anti-TxB2 (final dilution 1:1,000,000) were
mixed and added in a volume of 1.25 ml to each assay tube. The
smallest concentration that could be measured with 95% confi-
dence was 2 pg/mI. Consequently, the detection limit was 1 ng
of TxB2 per milliliter of plasma. Validation of TxB2 measure-
ments was obtained by dilution and recovery studies, and by
characterization of the thin-layer chromatographic distribution
of extracted TxB2-like immunoreactivities, as described else-
where [22, 231.
1-'4C Arachidonic acid uptake by washed platelet. Aliquots
of washed platelet suspension, prepared according to the meth-
od of Mustard et al [24], were incubated with 0, 2.0, and 4.0 g/dI
purified human serum albumin and 0.05 jiCi '4C-arachidonic
acid (sp act 54.6 Ci/mole; Amersham, England). After a 90-
mm incubation platelets were centrifuged, and supernatant
containing unincorporated AA was removed. Platelets were
resuspended in 5 ml of Tyrode-Hepes buffer and radioactivity
recovered in these platelet suspensions was expressed as a
percent of total '4C AA incorporated into platelets.
Radio-thin layer chromatography studies. Washed platelet
suspensions were incubated for 90 mm at 37°C with 0.1 pCi '4C-
AA in the absence of albumin. After incubation the labelled
platelets were centrifuged at x600g for 7 mm and resuspended
in Tyrode-Hepes buffer containing 1 m'vi CaC12 and 0, 2.0, or 4.0
g!dl fatty acid-poor bovine serum albumin. The concentration of
labelled platelets was adjusted to 3 x 108 platelets/ml. Two
milliliters of each preparation were stirred in an aggregometer
(ELVI 840, Logos, Italy) in the presence of 1 lU/mI of thrombin
(Topostasin®, Roche, Basel, Switzerland). After 5 mm, the
reaction was stopped by acidification to pH 3.5 with 2 N formic
acid, and lipids were extracted twice with 3 volumes of ethyla-
cetate [251. The organic extracts were dried over anhydrous
sodium sulfate, and concentrated under a stream of nitrogen.
The samples were applied together with unlabelled PG and
HETE standards to silica gel TLC plastic plates (DG-Kieselgel
fertigel-platte, Merck, Germany). The plates were developed in
a solvent system consisting of chloroform, methanol, acetic
acid, and water (90:8:1:0.8 vol/vol) [26]. Prostaglandin stan-
dards were located by exposure to iodine vapors. The silica gel
plates were divided into 32 segments, cut into sections, and
counted in a liquid scintillator counter (BF 50000 Berthold,
Germany) [27]. Radioactivity migrating with PG standards was
expressed as the percentage of total radioactivity recovered
from the plate. The generation of arachidonic acid metabolites
from platelets exposed to thrombin was compared to results
obtained with samples of labelled washed platelets stirred for 5
mm in the presence of normal saline.
Platelet aggregate ratio (PAR). The platelet aggregate ratio,
an estimate of circulating platelet aggregates, was determined
according to the method of Wu and Hoak [28]. In brief, venous
blood (0.5 ml) was drawn into syringes, containing either 2 ml of
buffered EDTA or 2 ml buffered EDTA/formalin. Blood sam-
ples were mixed and transferred into plastic tubes for 15 mm at
room temperature. After centrifugation at x 150 g for 10 mm,
platelet counts were obtained on both supernatant solutions.
The platelet aggregate ratio equals the platelet count in EDTA-
formalin/platelet count in EDTA.
Results
Malondialdehyde (MDA) and thromboxane B2 (TxB2)
production in platelet rich plasma
Platelet rich plasma from 19 patients with nephrotic syn-
drome and 30 normal control subjects were challenged with 0.25
to 1 m sodium arachidonate. The MDA production of nephrot-
ic PRP was significantly higher than that of normal PRP at all
AA concentrations used (Fig. I). Similarly, in the presence of 1
mM AA, the TxB2 production of nephrotic PRP was significant-
ly higher than the production observed in normal PRP (1451
90 ngI3 x 10 platelets versus 429 52 ng/3 x l0 platelets; five
experiments). Of interest is the apparent difference in the ratios
of MDA and TxB2 productions of nephrotic PRP/normal PRP
(1.5:1 ascompared to 3.4:1) when 1 mM AA was used. This may
be explained by the recent description of a thiobarbituric acid-
reactive substance different from MDA which has been shown
to be derived from the platelet lipoxygenase pathway [29].
Nonetheless, the differences in MDA and TxB2 production
were directionally similar and in substantial agreement. To
determine whether these differences were the consequence of a
plasma or platelet alteration, we performed mixing experiments
using washed platelets resuspended in normal or nephrotic
plasma.
MDA production and '4C-arachidonic acid metabolism in
washed platelet suspensions
Aliquots of washed platelet suspensions from nephrotic or
normal subjects were diluted in either normal or nephrotic
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Fig. 1. Production of MDA by platelet rich plasma obtained from
patients with nephrotic syndrome (open bars) and normal control
subjects (closed bars) following arachidonic acid stimulus (0.25-1.0
mM). The double asterisks represent P <0.001, by unpaired Student's
test.
plasma, and MDA production following the addition of 1 mM
sodium arachidonate was determined. As shown in Figure 2
nephrotic platelets resuspended in nephrotic plasma generated
a significantly higher amount of MDA than normal platelets
resuspended in normal plasma. The addition of normal plasma
to nephrotic platelets reduced MDA generation while the addi-
tion of nephrotic plasma to normal platelets increased MDA
production. These results indicate that the augmented MDA
production observed in nephrotic PRP is due to a plasma
alteration. This conclusion is confirmed by the fact that washed
normal and nephrotic platelets convert '4C-AA into equivalent
amounts of thromboxane B2 (17.5 1.7 and 18.0 1.7 percent
of total radioactivity recovered as TxB2, respectively).
Effect of albumin on the malondialdehyde and thromboxane
B2 generation of nephrotic PRP
To ascertain the effect of albumin on the MDA production of
nephrotic PRP, microliter amounts of purified albumin solution
(Immuno, Vienna, Austria) dialyzed against distilled water
were added to nephrotic PRP so as to provide final albumin
concentrations that varied between 2 and 4 g/dl. Platelet MDA
production significantly decreased as the albumin concentration
increased (Fig. 3). Similarly, TxB2 generation in the presence of
4 gIdl albumin was only 44.7 8.1% of the TxB2 production
observed with 2 g/dl albumin (five experiments). In similar
experiments, the presence of 3 and 4 g!dl gamma globulin failed
to alter platelet MDA production. These experiments demon-
strate that albumin decreases the conversion of AA to prosta-
glandins by nephrotic platelets. This inhibitory effect could be
due to either decreased AA uptake or decreased conversion of
AA into prostaglandin metabolites. To discriminate between
these possibilities, the handling of radiolabelled AA by washed
platelet suspensions containing 0, 2.0, or 4.0 gIdl albumin was
studied.
Effect of albumin on the uptake and conversion of '4C-AA by
normal platelets
In the absence of albumin, platelets incorporated 69.1 8.9%
of added '4C-AA. In the presence of 2.0 and 4.0 gIdl albumin,
'4C-AA uptakes were reduced to 31.6 5.2% and 7.4 1.5,
respectively. In separate experiments, chromatographic studies
demonstrated that the conversion of incorporated '4C-AA to
TxB2, PGs, and HETE by platelets following thrombin stimula-
tion also decreased as the albumin concentration increased and
left a larger proportion of '4C-AA unmetabolized (Fig. 4).
Effect of albumin infusion on platelet malondialdehyde
production in nephrotic patients
The inhibitory effect of albumin on platelet AA metabolism in
vitro led us to seek a comparable in vivo effect in patients with
nephrotic syndrome. Three patients received intravenous infu-
sions of 25% albumin (Siero Albumina Umana, Sclavo-Siena,
Italy; 1.5 ml/min for a total dose of 1 g/kg of body weight) and
platelet MDA productions pre- and 30 mm postinfusion were
compared. Plasma albumin levels increased from 2.0 0.3 to
3.6 0.6 g/dl following infusion. Figure 5 demonstrates that
albumin infusion markedly diminished platelet MDA produc-
tion in nephrotic patients.
Platelet-aggregate ratio in nephrotic patients
The marked increase in platelet prostaglandin formation
observed in patients with nephrotic syndrome suggests that
platelet hyperfunction may contribute to the thrombotic compli-
cations associated with this disorder. To obtain support for this
hypothesis, we measured the platelet aggregate ratio (PAR) in
patients with nephrotic syndrome during the acute phase of
their illness, and following remission when plasma albumin
levels had returned to normal (Fig. 6). The PAR was decreased
markedly during the acute phase of illness (0.67 0.03, albumin
concentration 1.9 0.2 g/dl) but returned to normal following
remission(0.90 0.03, albumin concentrations 4.45 0.25 g/dl;
P values for PAR and for albumin differences were both less
than 0.001).
Discussion
Our studies demonstrated that platelet MDA production
following arachidonic acid (AA) challenge was greater in ne-
phrotic than normal platelet rich plasma (PRP). Normal plasma
diminished the MDA production by nephrotic platelets while
nephrotic plasma augmented the MDA production by normal
platelets. These results suggest that the acceleration of AA
metabolism in nephrotic syndrome is due to a plasma rather
than a platelet alteration. This conclusion is supported by our
observation that albumin infusion, correcting the hypoalbumin-
emia of nephrotic syndrome, also diminished the excessive
production of MDA and TxB2 by platelets. Our results agree
with those of Yoshida and Aoki [10] and with those of Jackson
et al [14]. Although albumin decreased prostaglandin produc-
tion by nephrotic platelets following an AA challenge, Jackson
1.5
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et at report that it did not alter the prostaglandin production
which followed challenge with collagen [14]. Thus, nephrotic
platelets appear to respond differently to different stimuli. This
may explain why Stuart et at [12] were able to detect augmented
MDA production when washed nephrotic platelets were chal-
lenged with thrombin or N-ethyl maleimide (NEM), while we
were unable to distinguish nephrotic from normal platelets
when AA was the agonist.
The increased production of prostaglandins by nephrotic PRP
Fig. 2. Effect of normal and nephrotic plasma
on the MDA production of normal and
nephrotic platelets. Each column represents
the MDA production following the addition of
1 mM AA (three determinations). Note that
the level of MDA production was greater in
________ nephrotic syndrome (NS) plasma than normal
plasma (P < 0.05 for all normal NS plasma
comparisons as determined by Duncan's
multiple range test).
may be due to hypoalbuminemia and the consequent decrease
in AA binding [18, 30, 31]. Recently, however, Stuart, Gerrard,
and White [32] deffionstrated that the increased conversion of
AA to prostaglandins observed with low albumin concentra-
tions, was balanced by decreased AA release from platelet
phospholipids. Thus, net conversion of AA to TxB2 by normal
platelets did not change with variation in albumin concentra-
tion. On the other hand, AA release from platelet phospholipids
was increased by a low calcium concentration [32]. According-
ly, Stuart, Gerrard, and White reasoned that hypocalcemia, as
well as hypoalbuminemia, might contribute to the increased
platelet TxB2 production observed in nephrotic syndrome. Our
studies suggest an additional mechanism by which hypoalbu-
minemia could influence platelet prostaglandin production.
Both the uptake of '4C-AA by platelets and its subsequent
conversion to prostaglandins following thrombin stimulation
were inversely proportional to the albumin concentration. Con-
ceivably, hypoalbuminemia could lead to an increase in platelet
phospholipids and contribute to platelet "hyperactivity" in
nephrotic syndrome by permitting the accumulation of a larger
platelet source of AA.
Altered AA metabolism is not the only abnormality available
to explain platelet "hyperactivity" in nephrotic syndrome.
Elevated levels of cholesterol [33—35], low density lipoproteins
[33—35], and apolipoprotein B [35] are characteristic of nephrot-
4 ic syndrome. Hyperlipemia [36] and hypercholesterolemia [37]
are associated with increased platelet responsiveness to aggre-
gants and decreased responsiveness to prostacyclin [38]. Thus,
platelet hyperfunction in nephrotic syndrome may be the end
result of a number of contributing factors.
The platelet aggregate ratio (PAR), which measures circulat-
ing platelet aggregates, was initially abnormal in our patients.
This demonstrates the presence of activated platelets during the
acute phase of nephrotic syndrome and is consistent with the
increased plasma thromboglobulin levels [13, 15, 16] and de-
creased platelet survival times [12] reported by other investiga-
tors. Whether platelet activation and consumption necessarily
arise from platelet "hyperactivity" is problematic. Any throm-
botic event may activate platelets. Decreased platelet survival
[39], decreased PAR [40], and increased plasma thomboglobulin
[41] have all been observed in patients with deep vein thrombo-
sis. Although nephrotic platelets are hyperresponsive to AA,
platelet activation could be the consequence of any one of the
H
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Fig. 3. Effect of added albumin on the MDA production of nephrotic
PRP following AA stimulus (1 mM). Each point represents the mean
SE of values obtained in three different experiments. Note that MDA
production was inversely proportional to the albumin concentration (r
= 0.80; P < 0.001; linear regression analysis).
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Fig. 5. MDA production following AA stimulation in the PRP of three
patients with nephrotic syndrome before (open circles), and 30 mm
after (closed circles) the infusion of pur/1ed albumin solution. The
regression lines were determined by linear regression analysis.
Fig. 6. Platelet aggregate ratio in normal subjects (circles), and
patients with nephrotic syndrome during the acute phase of their illness
(triangles,), and following clinical remission (squares). All serum albu-
min concentrations were less than 2.7 g/dl during acute illness and
greater than 3.15 gIdl following remission.
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